HIGHLIGHTS
- who: Zhengchao Zhang from the The Chinese University of Hong Kong, Hong Kong SAR, China have published the Article: CAR-T Cells in the Treatment of Urologic Neoplasms: Present and Future, in the Journal: (JOURNAL)
- what: This study shows that VEGFR2-CAR T_cells are not satisfactory in the treatment of mRCC, but the side effects are acceptable. This study shows the importance of using CAR-T technology to target antigens produced or increased during tumor therapy. The aim of the clinical study was to evaluate the safety and efficacy of different gene-editing CAR-T_cell . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.